Scotland Moves Another Step Closer to Global Leadership in Stem Cell Research
ITI Life Sciences Initiates £9.5 million R&D Programme to Develop Human Stem Cells for Pharmaceutical Research with University of Glasgow and Cellartis
Scotland launched a new £9.5 million R&D programme by ITI Life Sciences (Dundee, Scotland) to develop an automated process to produce high-quality human stem cells. This capability does not exist anywhere in the world and its development shall put Scotland at the forefront of stem cell research as well as bringing closer the use of stem cells as therapeutics. As part of this three-year programme, Swedish biotech company Cellartis AB is setting up an R&D and manufacturing facility in Dundee. The ITI programme will also involve the University of Glasgow, which brings world-class expertise in the molecular mechanisms that control cell signalling and development. The work will be carried out by the University's Faculty of medicine and Faculty of Biomedical and Life Sciences. In bringing together this programme, ITI life science hopes to solve some of the main problems associated with producing high volumes of quality stem cells.
Stem cell research offers huge potential for the life science sector in Scotland. Scottish academic studies in this field, as well as the location of a number of international stem cell players here means it is viewed as one of the country's major strengths. The ITI programme and its focus on collaborative research will accelerate Scottish activity in this area and provide an endorsement of Scotland's prominence.
Other news from the department science
